Induction of cytomegalovirus-specific CD4+ cytotoxic T lymphocytes from seropositive or negative healthy subjects or stem cell transplant recipients

Experimental Hematology

Volumn 32, Issue 1, 2004, Pages 95-103

  Tazume, Kei ^a   Hagihara, Masao ^a   Gansuvd, Balgansuren ^a   Higuchi, Ayako ^a   Ueda, Yoko ^a   Hirabayashi, Kaoru ^a   Hojo, Motoharu ^a   Tanabe, Akiko ^a   Okamoto, Ayako ^a   Kato, Shunichi ^a   Hotta, Tomomitsu ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD14 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHROMIUM 51; FAS ANTIBODY; HLA ANTIBODY; HLA DR ANTIGEN; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; PERFORIN; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR; VIRUS ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BIOASSAY; CELL ACTIVITY; CELL CULTURE; CELL KILLING; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DENDRITIC CELL; DERIVATIZATION; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MEASUREMENT; MONOCYTE; MONONUCLEAR CELL; PATIENT; PHENOTYPE; PRIORITY JOURNAL; RECIPIENT; SERODIAGNOSIS; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; VOLUNTEER;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 9144240431     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2003.10.008     Document Type: Article

References (52)

1. Einsele H., Hebart H., Kauffmann-Schneider C., et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 25:2000;757-763.
2. Einsele H., Ehninger G., Steidle M., et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet. 338:1991;1170-1172.
3. van Zanten J., Harmsen M.C., van der Giessen M., et al. Humoral immune response against human cytomegalovirus (HCMV)-specific proteins after HCMV infection in lung transplantation as detected with recombinant and naturally occurring proteins. Clin Diagn Lab Immunol. 2:1995;214-218.
4. Kern F., Faulhaber N., Frommel C., et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol. 30:2000;1676-1682.
5. Applebaum F.R., Meyers J.D., Fefer A., et al. Nonbacterial nonfungal pneumonia following marrow transplantation in 100 identical twins. Transplantation. 33:1982;265-268.
6. Miller D.L., el-Ashry D., Cheville A.L., Liu Y., McLeskey S.W., Kern F.G. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ. 5:1994;1263-1274.
7. Einsele H., Rauser G., Grigoleit U., et al. Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide. Cytotherapy. 4:2002;49-54.
8. Riddell S.R. Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts. Semin Respir Infect. 10:1995;199-208.
9. Greenberg P.D., Nelson B., Gilbert M., et al. Genetic modification of T cell clones to improve the safety and efficacy of adoptive T cell therapy. Ciba Found Symp. 187:1994;212-223. discussion 224-218.
10. Walter E.A., Greenberg P.D., Gilbert M.J., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 333:1995;1038-1044.
11. Komanduri K.V., Donahoe S.M., Moretto W.J., et al. Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects. Virology. 279:2001;459-470.
12. Asanuma H., Sharp M., Maecker H.T., Maino V.C., Arvin A.M. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis. 181:2000;859-866.
13. Rentenaar R.J., Gamadia L.E., van DerHoek N., et al. Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection. J Clin Invest. 105:2000;541-548.
14. Gamadia L.E., Rentenaar R.J., Baars P.A., et al. Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. Blood. 98:2001;754-761.
15. Lowin B., Hahne M., Mattmann C., Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 370:1994;650-652.
16. Kagi D., Vignaux F., Ledermann B., et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 265:1994;528-530.
17. Rouvier E., Luciani M.F., Golstein P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med. 177:1993;195-200.
18. Ando K., Hiroishi K., Kaneko T., et al. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol. 158:1997;5283-5291.
19. Gagnon S.J., Ennis F.A., Rothman A.L. Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones. J Virol. 73:1999;3623-3629.
20. Marsters S.A., Sheridan J.P., Pitti R.M., et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol. 7:1997;1003-1006.
21. Holtappels R., Podlech J., Geginat G., Steffens H.P., Thomas D., Reddehase M.J. Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates. J Virol. 72:1998;7201-7212.
22. Hahn S., Gehri R., Erb P. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev. 146:1995;57-79.
23. Stalder T., Hahn S., Erb P. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol. 152:1994;1127-1133.
24. Yasukawa M., Ohminami H., Arai J., Kasahara Y., Ishida Y., Fujita S. Granule exocytosis, and not the fas/fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4(+) as well as CD8(+) cytotoxic T lymphocytes in humans. Blood. 95:2000;2352-2355.
25. Appay V., Zaunders J.J., Papagno L., et al. Characterization of CD4(+) CTLs ex vivo. J Immunol. 168:2002;5954-5958.
26. Zhou L.J., Tedder T.F. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA. 93:1996;2588-2592.
27. Szabolcs P., Ciocon D.H., Moore M.A., Young J.W. Growth and differentiation of human dendritic cells from CD34+ progenitors. Adv Exp Med Biol. 417:1997;15-19.
28. Rosenzwajg M., Canque B., Gluckman J.C. Human dendritic cell differentiation pathway from CD34+ hematopoietic precursor cells. Blood. 87:1996;535-544.
29. Akbari O., DeKruyff R.H., Umetsu D.T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol. 2:2001;725-731.
30. McGuirk P., McCann C., Mills K.H. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med. 195:2002;221-231.
31. Schlienger K., Craighead N., Lee K.P., Levine B.L., June C.H. Efficient priming of protein antigen-specific human CD4(+) T cells by monocyte-derived dendritic cells. Blood. 96:2000;3490-3498.
32. Zhu J., Shearer G.M., Marincola F.M., et al. Discordant cellular and humoral immune responses to cytomegalovirus infection in healthy blood donors: existence of a Th1-type dominant response. Int Immunol. 13:2001;785-790.
33. Savoldo B., Cubbage M.L., Durett A.G., et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 168:2002;909-918.
34. Lucas K.G., Sun Q., Burton R.L., et al. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants. Hum Gene Ther. 11:2000;1453-1463.
35. Peggs K., Verfuerth S., Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood. 97:2001;994-1000.
36. Menges M., Rossner S., Voigtlander C., et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med. 195:2002;15-21.
37. Granucci F., Vizzardelli C., Virzi E., Rescigno M., Ricciardi-Castagnoli P. Transcriptional reprogramming of dendritic cells by differentiation stimuli. Eur J Immunol. 31:2001;2539-2546.
38. Hsieh S.M., Pan S.C., Hung C.C., et al. Kinetics of antigen-induced phenotypic and functional maturation of human monocyte-derived dendritic cells. J Immunol. 167:2001;6286-6291.
39. O'Sullivan B.J., Thomas R. CD40 ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-kappaB. J Immunol. 168:2002;5491-5498.
40. Wills M.R., Carmichael A.J., Mynard K., et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol. 70:1996;7569-7579.
41. Kleihauer A., Grigoleit U., Hebart H., et al. Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells. Br J Haematol. 113:2001;231-239.
42. Szamania S., Galloway A., Bruorton M., et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood. 98:2001;505-512.
43. Lindsley M.D., Torpey D.J. 3rd, Rinaldo C.R. Jr. HLA-DR-restricted cytotoxicity of cytomegalovirus-infected monocytes mediated by Leu-3-positive T cells. J Immunol. 136:1986;3045-3051.
44. Ghanekar S.A., Nomura L.E., Suni M.A., Picker L.J., Maecker H.T., Maino V.C. Gamma interferon expression in CD8(+) T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65. Clin Diagn Lab Immunol. 8:2001;628-631.
45. Knight D.A., Waldman W.J., Sedmak D.D. Human cytomegalovirus does not induce human leukocyte antigen class II expression on arterial endothelial cells. Transplantation. 63:1997;1366-1369.
46. Cebulla C.M., Miller D.M., Zhang Y., et al. Human cytomegalovirus disrupts constitutive MHC class II expression. J Immunol. 169:2002;167-176.
47. Mourafrsi M., Mehl A.M., Borysiewicz L.K., Tabi Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood. 99:2002;2913-2921.
48. Yasukawa M., Ohminami H., Yakushijin Y., et al. Fas-independent cytotoxicity mediated by human CD4+ CTL directed against herpes simplex virus-infected cells. J Immunol. 162:1999;6100-6106.
49. Sun Q., Burton R.L., Lucas K.G. Cytokine production and cytolytic mechanism of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures. Blood. 99:2002;3302-3309.
50. Gansuvd B., Hagihara M., Yu Y., et al. Human umbilical cord blood NK T cells kill tumors by multiple cytotoxic mechanisms. Hum Immunol. 63:2002;164-175.
51. Hengel H., Lucin P., Jonjic S., Ruppert T., Koszinowski U.H. Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J Virol. 68:1994;289-297.
52. Kondo A., Sidney J., Southwood S., et al. Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. J Immunol. 155:1995;4307-4312.